Asia PR News

GOTHENBURG, Nov. 29 /PRNewswire-AsiaNet/ –

Cellectricon today announced the launch of the new Dynaflow(TM) Pro II
System for safety pharmacology studies. The system comes with the newly
developed DF-8 Pro II Chip successfully beta-tested for conducting GLP hERG
studies by Swiss ion channel CRO bSys GmbH.

Developed for life scientists and drug discovery researchers, the Dynaflow
System is an add-on to conventional patch-clamp and provides a solution to the
current need for increased throughput and data quality in ion channel drug
discovery. The system now comes with the newly developed Dynaflow 8-channel
microfluidic chip (DF-8 Pro II Chip) designed for cumulative dose-response
work and/or screening of slow acting compounds on non-desensitizing ion
channels. The new DF-8 Pro II Chip has been beta-tested by the Swiss ion
channel CRO bSys GmbH, who studied a variety of hERG inhibitory substances
with results demonstrating the system performance as ideally suited for safety
pharmacology studies.

Dr. Med. Daniel Konrad, CEO of bSys GmbH, said, "We have incorporated the
Dynaflow system and the new DF-8 Pro II Chip into our cardiac safety
assessment services. The system enabled us to perform standardized and
reproducible GLP hERG studies of ion channels with outstanding data quality."

"We’ve developed the new DF-8 Pro II Chip and Dynaflow Pro II Platform to
meet the increasing demand for a system with safety pharmacology performance,"
stated Mattias Karlsson, Ph.D., VP R&D at Cellectricon. "With the new Dynaflow
Pro II System and Dynaflow Microfluidic Chips (8-, 16- and 48- channels),
Cellectricon now offers a complete product range for ion channel drug
discovery."

About Cellectricon
Cellectricon AB (Gothenburg, Sweden) invents and develops new types of
functional cell-based screening devices for applications in drug discovery and
basic research. The company utilizes state-of-the-art interfaces to biological
systems by employing novel microfabrication technologies and smart engineering
solutions. This enables completely new types of assays and devices with
superior performance characteristics and robustness. Cellectricon’s products
are designed to enable substantial increases in productivity at the highest
data quality. The company was formed in 2000 based on an extensive and solid
patent portfolio within different areas such as high-throughput
electrophysiology, microfluidics, microfabrication and electroporation.
Cellectricon is a privately held company and the main shareholders are
InnovationsKapital, Investor Growth Capital and Karolinska Investment Fund.

SOURCE: Cellectricon AB

CONTACT: Susanne Orwar, Communications Manager, Cellectricon
+46 (0)31 760 35 15, susanne.orwar@cellectricon.se